SASTASUNDR2023-10-012023-12-31 SASTASUNDR2023-10-012023-12-31 SASTASUNDR2023-10-012023-12-31in-bse-fin:OneOtherRevenueFromOperations01Member SASTASUNDR2023-10-012023-12-31in-bse-fin:FourOtherRevenueFromOperations01Member SASTASUNDR2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member SASTASUNDR2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member SASTASUNDR2023-12-31 SASTASUNDR2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue01Member SASTASUNDR2023-10-012023-12-31in-bse-fin:OneReportableSegmentRevenue02Member SASTASUNDR2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue01Member SASTASUNDR2023-10-012023-12-31in-bse-fin:FourReportableSegmentRevenue02Member SASTASUNDR2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults01Member SASTASUNDR2023-10-012023-12-31in-bse-fin:OneReportableSegmentResults02Member SASTASUNDR2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults01Member SASTASUNDR2023-10-012023-12-31in-bse-fin:FourReportableSegmentResults02Member SASTASUNDR2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets01Member SASTASUNDR2023-10-012023-12-31in-bse-fin:OneReportableSegmentAssets02Member SASTASUNDR2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities01Member SASTASUNDR2023-12-31in-bse-fin:OneReportableSegmentLiabilities01Member SASTASUNDR2023-12-31 SASTASUNDR2023-10-012023-12-31in-bse-fin:OneReportableSegmentLiabilities02Member SASTASUNDR2023-12-31in-bse-fin:OneReportableSegmentLiabilities02Member SASTASUNDR2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SASTASUNDR2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 533259 SASTASUNDR NOTLISTED Sastasundar Ventures Limited Equity 2023-04-01 2024-03-31 2024-01-31 2024-01-22 INR Lakhs Third quarter 2024-01-31 14:30:00 2024-01-31 16:00:00 false Not applicable Multi segment 2023-10-01 2023-12-31 Unaudited Consolidated 1755000.00 284000.00 0.00 0.00 71001000.00 0.00 3649859000.00 17940000.00 4132000.00 3744971000.00 201333000.00 3946304000.00 3239000.00 3194881000.00 159243000.00 123197000.00 2424000.00 23143000.00 0.00 0.00 0.00 0.00 230147000.00 3736274000.00 210030000.00 0.00 210030000.00 10802000.00 -2719000.00 8083000.00 201947000.00 0.00 0.00 0.00 -234243000.00 -32296000.00 -252000.00 -32548000.00 -7460000.00 -24836000.00 -7714000.00 -24834000.00 318105000.00 10 -0.23 -0.23 0.00 0.00 -0.23 -0.23 3. During the previous year, the Board of Directors at its meeting held on 27th March, 2023 approved a Composite Scheme of Arrangement (the Scheme) for Demerger and Amalgamation amongst Sastasundar Ventures Limited (‘Demerged Company’ or ‘Amalgamated Company’) and Microsec Resources Private Limited (“Resulting Company”) and Sastasundar Healthbuddy Limited (“Amalgamating Company”) under Sections 230 to 232 and other relevant provisions of the Companies Act, 2013 and the rules made there under, with effect from 1st April, 2023 (the Appointed Date). Upon receipt of requisite approvals of the concerned regulatory authorities, the scheme will be recognised in the financial results. As per the provisions of paragraph 3(b) of Part 1(A) of the SEBI Master Circular dated June 20, 2023, the Amalgamated company (post Amalgamation) is required to maintain pre-public shareholding of minimum 25% including QIB of Amalgamating Company. As a part of the process, the company has filed an application with Securities and Exchange Board of India (SEBI) seeking exemption from the aforesaid provision of SEBI Master Circular dated June 20, 2023, for consideration of Mitsubishi Corporation, Japan and Rohto Pharmaceuticals Company Limited, Japan, the public shareholder of Amalgamating Company as public shareholders of Amalgamated Company. We hereby inform that SEBI vide letter dated January 30, 2024 has informed the company that the competent authority has not acceded the company’s request. The Designated Stock Exchange has not granted approval to the Scheme. The Company is exploring for appropriate steps in this regard for further course of action. 4. Exceptional items represent the gain on following transaction/ event: During the previous year, the management based on its internal assessment, has detected misappropriation of cash collections from customers aggregating to Rs. 796.45 lakhs (Sastasundar Healthbuddy Limited- Rs. 161.40 Lakhs) (Retailer Shakti Supply Chain Pvt Ltd- Rs. 635.05 Lakhs) by few employees of the Sastasundar Healthbuddy Limited (“SHBL”), subsidiary of the company and Retailer Shakti Supply Chain Pvt Ltd (RSCPL), step down subsidiary of the company. SHBL has referred the matter to the police department and after filing of the First Information Report (FIR), the aforesaid employees were arrested by the police and an investigation charge sheet has been filed with the Additional Chief Judicial Magistrate, Baruipur, West Bengal by the police. SHBL and RSCPL has expensed the aforesaid amount during the previous year under the heading “exceptional item” and the SHBL is taking necessary legal action to recover the amount. 5. Happymate Foods Limited, step down subsidiary of the company had started its operation in fast moving consumer goods in 2018 with an aim to reach the consumer with a premium brand. The company has taken various steps since then to build distribution channel & offline stores, which did not turn out as expected and losses has been incurred. Presently the company is into discussion with business partner on further plans of restructuring its business. 6. During the current quarter, Sastasundar Healthbuddy Limited (SHBL) subsidiary of the Company's Trade Payables as of December 31, 2023 are net of debit note balance of Rs. 991.84 lakhs related to the return of goods (generally medicine). There is a time lag between issue of credit notes by the suppliers against the debit notes raised by the Company. The management is in the process of matching the debit note with corresponding credit note issued by the vendor and reconciling the outstanding balance of debit notes as at December 31, 2023. Multi segment 2023-04-01 2023-12-31 Unaudited Consolidated 5346000.00 1462000.00 0.00 0.00 99512000.00 0.00 10466410000.00 56508000.00 61152000.00 10690390000.00 419469000.00 11109859000.00 15196000.00 9166410000.00 329739000.00 370800000.00 7344000.00 66101000.00 0.00 0.00 0.00 0.00 647592000.00 10603182000.00 506677000.00 0.00 506677000.00 98391000.00 -169740000.00 -71349000.00 578026000.00 0.00 0.00 0.00 -735217000.00 -157191000.00 -563000.00 -157754000.00 -75528000.00 -81663000.00 -76151000.00 -81603000.00 318105000.00 10 -2.37 -2.37 0.00 0.00 -2.37 -2.37 Other Financial Income 4132000.00 Other Financial Income 61152000.00 Other expenses 230147000.00 Other expenses 647592000.00 0.00 0.00 0.00 0.00 Financial Services 77170000.00 Healthcare Network 3667801000.00 Financial Services 167471000.00 Healthcare Network 10522919000.00 3744971000.00 10690390000.00 3744971000.00 10690390000.00 Financial Services 72192000.00 Healthcare Network -53704000.00 Financial Services 151065000.00 Healthcare Network -29015000.00 18488000.00 122050000.00 2424000.00 7344000.00 -193966000.00 -391971000.00 210030000.00 506677000.00 Financial Services 758872000.00 Healthcare Network 10651159000.00 11410031000.00 485274000.00 11895305000.00 Financial Services 37179000.00 Healthcare Network 2075387000.00 2112566000.00 4849000.00 2117415000.00 The Group has identified the following segments : (a) Financial Services - consists mainly of financing of loans and investment in shares and securities, financial consultancy, professional fees, wealth management, financial planning, distribution and related services. (b) Healthcare Network - includes activities for pathology and marketing of healthcare and OTC products through e-commerce portal and diagnostic services which consist of pathological / radiological investigations. Remeasurement gain/(loss) on defined benefit plans -296000.00 Remeasurement gain/(loss) on defined benefit plans -713000.00 -296000.00 -713000.00 -44000.00 -150000.00 -252000.00 -563000.00